Company intelligence / Profile preview

Inventiva Media Group

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Inventiva is a clinical-stage biopharmaceutical company developing novel oral small molecule therapies targeting significant unmet needs in fibrosis-related diseases and lysosomal storage disorders. Its lead candidate lanifibranor has shown anti-fibrotic activity in NASH and systemic sclerosis. Odiparcil targets rare genetic disorders such as mucopolysaccharidosis VI. The company also maintains a pipeline of early-stage oncology programs.

Therapeutic areas: Rare DiseasesGastroenterologyRheumatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Inventiva Media Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inventiva Media Group.

Explore the full profile